Kaplan-Meier overall survival (OS) and event-free survival (EFS)... | Download Scientific Diagram
First Randomized Trial to Show Benefit of Tyrosine Kinase Inhibitor in Newly Diagnosed Acute Myeloid Leukemia - The ASCO Post
The Expression Pattern of the Pre-B Cell Receptor Components Correlates with Cellular Stage and Clinical Outcome in Acute Lymphoblastic Leukemia | PLOS ONE
Reduced–dose intensity therapy for pediatric lymphoblastic leukemia: long-term results of the Recife RELLA05 pilot study - ScienceDirect
Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols | Haematologica
Event-free survival (EFS) curves for children with acute lymphoblastic... | Download Scientific Diagram
Overall survival and event-free survival according to primary... | Download Scientific Diagram
Cancers | Free Full-Text | Outcome of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse–Bordeaux DATAML Registry Study
Ivosidenib + azacitidine ups event-free survival in IDH1-mutated acute myeloid leukemia
Kaplan-Meier overall survival and event free survival curves of acute... | Download Scientific Diagram
The Kaplan–Meier analysis of 5-year event-free survival and overall... | Download Scientific Diagram
Event free survival of 71 children with acute lymphoblastic leukemia... | Download Scientific Diagram
Blinatumomab Effective for Children with Relapsed Leukemia - NCI
Single‑cell RNA sequencing of t(8;21) acute myeloid leukemia for risk prediction
A) Overall survival, (B) relapse-free survival, and (C) event-free... | Download Scientific Diagram
Cancers | Free Full-Text | Real-World Outcomes of Patients with Refractory or Relapsed FLT3-ITD Acute Myeloid Leukemia: A Toulouse-Bordeaux DATAML Registry Study
Treatment of Acute Lymphoblastic Leukemia -- 30 Years' Experience at St. Jude Children's Research Hospital | NEJM
ASH 2022: FLAG-Ida Combined with Gemtuzumab Ozogamicin (GO) Improves Event Free Survival in Younger Patients with Newly Diagnosed Acute Myeloid Leukaemia (AML) and Shows an Overall Survival Benefit in NPM1 and FLT3
SciELO - Brasil - Acute lymphoblastic leukemia in children and adolescents: prognostic factors and analysis of survival Acute lymphoblastic leukemia in children and adolescents: prognostic factors and analysis of survival
A novel event-free survival endpoint in locally advanced pancreatic cancer - Pascal Hammel, Ewa Carrier, Mairead Carney, Mark Eisner, Thomas Fleming, 2021
Prognostic factors and treatment of pediatric acute lymphoblastic leukemia
Event-free survival (EFS) and overall survival (OS) according to risk... | Download Scientific Diagram
A) Overall survival and (B) event-free survival for the subgroup of... | Download Scientific Diagram
